CN115010822A - Armillariella tabescens mycelium polysaccharide and its application - Google Patents
Armillariella tabescens mycelium polysaccharide and its application Download PDFInfo
- Publication number
- CN115010822A CN115010822A CN202210649789.8A CN202210649789A CN115010822A CN 115010822 A CN115010822 A CN 115010822A CN 202210649789 A CN202210649789 A CN 202210649789A CN 115010822 A CN115010822 A CN 115010822A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- tabescens
- ulcer
- armillaria
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a polysaccharide of mycelia of armillaria tabescens and application thereof, wherein the monosaccharide composition and the molar ratio of the polysaccharide of mycelia of armillaria tabescens are that mannose, galacturonic acid, glucose and arabinose are 9.83:14.52:17.45: 8.63; the molecular weight of the Armillariella tabescens mycelium polysaccharide is 2.95 × 10 4 Da. Animal experiments show that Armillariella tabescens mycelium polysaccharide PAT-W can significantly reduce the level of inflammatory factors of ulcer tissues, increase the content of epidermal growth factors, reduce inflammatory cell infiltration, promote ulcer surface healing and regulate the imbalance of oral flora caused by ulcer. The Armillaria tabescens mycelium polysaccharide PAT-W can be used as a novel natural active substance for treating oral ulcer, and can be widely applied to the fields of medicine and oral care.
Description
Technical Field
The invention belongs to the technical field of biological medicine preparation, and particularly relates to armillaria tabescens mycelium polysaccharide and application thereof.
Background
Oral ulcers are the most common in oral mucosal diseases and have many causes, for example, mental stress, immune disorders, endocrine disorders, nutrient deficiency, trauma, oral flora disorders, and the like. Although the traditional Chinese medicine has certain self-healing property, once the disease occurs, the affected part is hard to feel burning pain, the serious patient can influence the eating and the speaking, the disease is hard to cure radically, and the traditional Chinese medicine has the repeatability and brings great inconvenience to the work and the life of people. The treatment of the oral ulcer is mainly symptomatic treatment, local inflammatory reaction is relieved by inhibiting immune function, the immunity of the organism is adjusted, and antibiotics and antibacterial drugs are used, but the repeated use of the antibacterial drugs and the antibiotics is easy to cause drug resistance and other side reactions of the organism. Or local medicines such as buccal tablets, medicinal films, ointments and the like are applied to achieve the aim of relieving pain, but the relation between the material basis and the efficacy of active ingredients is to be determined; moreover, the medicinal components with pungent odor such as medicinal membrane and ointment enter the body after entering the mouth, and certain side effects such as retching and acid regurgitation can be generated. In recent years, natural bioactive substances having high efficiency and no side effects have attracted attention. Researches prove that the natural active polysaccharides such as bletilla striata and aloe polysaccharide have the function of treating dental ulcer.
Armillaria millitarietabescens (Scop. EX. Fr) Sing, a precious medicinal fungus unique to China, contains natural active ingredients such as armillarisin and B, and is widely used for treating acute and chronic hepatitis, appendicitis, otitis media and cholecystitis. The polysaccharide is used as an important natural active substance generated in the growth process of the armillaria tabescens, has pharmacological actions of immunoregulation, antibiosis, blood sugar and fat reduction, intestinal micro-ecological disorder improvement and the like, and the action of treating the oral ulcer is reported in documents. The applicant proves that the Armillariella tabescens polysaccharide PAT-W has the obvious function of treating the oral ulcer by evaluating indexes such as the level of inflammatory factors of oral mucosa tissues, the release amount of epidermal growth factors, the polymorphism regulation of oral flora and the like.
Disclosure of Invention
The invention aims to provide a armillaria tabescens mycelium polysaccharide and an application thereof. The armillariella active polysaccharide PAT-W with specific chemical composition is prepared by removing impurities such as protein, pigment and the like in an aqueous extract by a polyamide method, an ultrafiltration membrane separation method and an AKTADAEE-FF ion chromatography technology, and has obvious curative effect on oral ulcer. The armillariella mycelium polysaccharide can be widely applied to the pharmaceutical and daily chemical industries, such as the research and development of oral ulcer sprays and nursing toothpaste containing the armillariella mycelium polysaccharide, and has important development prospect and market application value.
The invention relates to a polysaccharide of mycelia of armillaria tabescens, which comprises monosaccharide with the molar ratio of mannose to galacturonic acid to glucose to arabinose of 9.83:14.52:17.45:8.63 and has the molecular weight of 2.95 multiplied by 10 4 Da。
The preparation method of the armillaria mycelium polysaccharide comprises the following steps:
step 1: 4-6g of Armillaria tabescens (Scop. EX. Fr.) Sing strain (available from Hefeicheng Biopharmaceutical Co., Ltd.) was inoculated into 1000mL of glucose-potato-MgSO 4 Standing and culturing at 28 deg.C for 15 days in culture medium to obtain artificial liquid, standing and fermenting mycelia of Armillariella tabescens;
step 2: crushing the armillaria mycelia (2000g) obtained in the step 1, adding distilled water according to the liquid-material ratio of 1g:10mL, leaching at 90 ℃ for 3 hours, repeatedly leaching for 3 times, and combining the extracting solutions;
and step 3: concentrating the extract obtained in step 2 to 1/250 of the original volume, adding 95% ethanol of 4 times volume, standing at 4 deg.C for 12h, centrifuging at 4500rpm for 10-15min, and collecting precipitate;
and 4, step 4: dissolving the precipitate obtained in the step 3 with distilled water, and decoloring and deproteinizing by a polyamide method to obtain crude polysaccharide of the mycelia of the armillaria tabescens;
and 5: preparing the crude polysaccharide obtained in step 4 into a solution of 100mg/mL, and passing through an ultrafiltration membrane to obtain a solution with the molecular weight cutoff of 1 × 10 4 Da and 1X 10 5 Da is classified, and the trapped fluid of the molecular weight components is concentrated and freeze-dried; preparing polysaccharide solution of 100mg/mL5mL from the polysaccharide after ultrafiltration and freeze drying, passing through DEAE-FF anion exchange chromatographic column, eluting with double distilled water and 0.5moL/mL sodium chloride isocratic at flow rate of 1mL/min, collecting by tube, dialyzing to remove sodium chloride, and freeze drying. Adopts double distilled water as mobile phaseThe eluent component is detected to be a uniform component (PAT-W) by the Jieren HPLC-ELSD liquid chromatography.
In step 1, the glucose-potato-MgSO 4 The culture medium is obtained by the following method: peeling and cutting 300g potato, boiling for 15min, filtering, mixing with 20g glucose and 5g MgSO 4 Mixing, adding water to 1000mL, sterilizing at 121 deg.C for 20min to obtain glucose-potato-MgSO 4 A culture medium;
in the step 4, the conditions for decoloring and deproteinizing by a polyamide method are as follows: 80g of 100-mesh 120-mesh polyamide and 300mL of precipitate solution are uniformly mixed in a 500mL shaking flask, and the mixture is shaken for 30min at the room temperature by 200rpm of a shaking table to fully adsorb protein and pigment, then liquid is filtered, and filtrate is collected, concentrated and freeze-dried to obtain crude polysaccharide.
The armillariella mycelium polysaccharide can obviously reduce the level of inflammatory factors, improve the content of epidermal growth factors, reduce inflammatory cell infiltration and adjust the richness and uniformity of oral flora, thereby being capable of treating oral ulcer.
The Armillariella tabescens mycelium polysaccharide is tasteless, white powder, and colorless and transparent aqueous solution. The polysaccharide solution makes up for the deficiency of other medicine films, ointments and other medicines with pungent odor entering the body after entering the body to cause vomit, acid regurgitation and the like.
The invention relates to an application of armillaria tabescens mycelium polysaccharide in preparing a medicinal preparation for treating oral ulcer. The armillariella mycelium polysaccharide has the effects of remarkably relieving inflammation injury of the oral mucosa ulcer surface, improving the release of epidermal growth factors to promote the healing of the oral mucosa ulcer surface, regulating the imbalance of oral flora and the like.
The invention takes a rat suffering from oral ulcer induced by combination of mechanical trauma and staphylococcus aureus as a research object, and animal experiments prove that the armillariella mycelium polysaccharide has the effect of treating the oral ulcer.
The armillariella mycelium polysaccharide has a remarkable improvement effect on oral flora imbalance of rats with oral ulcer.
Drawings
FIG. 1 is a standard monosaccharide composition liquid chromatogram (. star. -solvent peak, Man-mannose, Rha-rhamnose, GlcA-glucuronic acid, GalA-galacturonic acid, Glc-glucose, Gal-galactose, Ara-arabinose, Fuc-galactose).
FIG. 2 is a liquid chromatogram of polysaccharide monosaccharide composition of mycelia of Armillariella tabescens (Man-mannose, GalA-galacturonic acid, Glc-glucose, Ara-arabinose).
FIG. 3 is relative molecular mass chromatogram of detection of Armillariella tabescens mycelium polysaccharide PAT-W.
FIG. 4 shows the effect of Armillaria tabescens mycelium polysaccharide on the pathological condition of mucous membrane tissue of rat with oral ulcer
FIG. 5 is the effect of Armillaria tabescens mycelium polysaccharide on the alpha diversity of oral flora in rats with oral ulcer
FIG. 6 is the effect of Armillaria tabescens mycelium polysaccharide on oral flora beta diversity in canker sore rats.
Detailed Description
The preparation of the present invention, reducing inflammatory factors of ulcer tissues, promoting the release of epidermal growth factors and wound healing, and regulating oral flora polymorphisms are described in the following by specific examples, which are only used for explaining the present invention and are not intended to limit the scope of the present invention.
Example 1: preparation of Armillariella tabescens mycelium and polysaccharide PAT-W
Step 1: peeling and cutting 300g potato, boiling for 15min, filtering, 20g glucose and 5g MgSO 4 Adding water to 1000mL, sterilizing at 121 deg.C for 20min to obtain glucose-potato-MgSO 4 A culture medium; 4-6g Armillariella tabescens (Scop. EX. Fr) Sing strain (provided by Hefeicheng Biopharmaceutical Co., Ltd.) was inoculated into 1000mL of glucose-potato-MgSO 4 Standing and culturing at 28 deg.C for 15 days in culture medium to obtain artificial liquid, standing and fermenting mycelia of Armillariella tabescens;
step 2: crushing the armillaria mycelia (2000g) obtained in the step 1, adding distilled water according to the liquid-material ratio of 1:10(g/mL), leaching for 3 hours at 90 ℃, repeatedly leaching for 3 times, and combining the extracting solutions;
and step 3: concentrating the extract obtained in step 2 to 1/250 of the original volume, adding 95% ethanol of 4 times volume, standing at 4 deg.C for 12h, centrifuging at 4500rpm for 10-15min, and collecting precipitate;
and 4, step 4: and (3) dissolving the precipitate obtained in the step (3) with distilled water, and decoloring and deproteinizing by a polyamide method to prepare the crude polysaccharide of the mycelia of the armillaria tabescens. The conditions are as follows: 80g of 100-mesh 120-mesh polyamide and 300mL of precipitate solution are uniformly mixed in a 500mL shaking flask, and the mixture is shaken for 30min at the room temperature by 200rpm of a shaking table to fully adsorb protein and pigment, then liquid is filtered, and filtrate is collected, concentrated and freeze-dried to obtain crude polysaccharide.
And 5: preparing the crude polysaccharide obtained in step 4 into a solution of 100mg/mL, and passing through an ultrafiltration membrane to obtain a solution with the molecular weight cutoff of 1 × 10 4 Da and 1X 10 5 Da is subjected to fractionation, and the components of the retentate with the molecular weight between the two fractions are concentrated and freeze-dried. Preparing 1mL of solution with the concentration of 100mg/mL of polysaccharide after ultrafiltration and freeze-drying, passing through a DEAE-FF anion exchange column, eluting with double distilled water and sodium chloride at the flow rate of 1mL/min in a 5 mL/tube, recording as PAT-W after dialysis and freeze-drying, and measuring the total sugar content to be 97.88% by a phenol-sulfuric acid method.
Example 2: monosaccharide composition and molecular weight of Armillariella tabescens mycelium polysaccharide PAT-W
The analysis of the monosaccharide composition of PAT-W adopts acid hydrolysis-PMP (1-phenyl-3-methyl-5-pyrazolone) derivatization method to process samples, and high performance liquid chromatography analysis and determination. 5mg of PAT-W is weighed and dissolved in 5mL of 2mol/L trifluoroacetic acid, the tube is sealed by nitrogen, and the solution is subjected to oil bath at 110 ℃ for 8h for full acidolysis. And (3) rotating out the acidic component by a rotary evaporator, adding a proper amount of deionized water, repeatedly rotating and steaming until the pH value of the solution is neutral, and adding 1mL of distilled water for later use.
Step 1: mu.L of 0.5mol/L of methanol solution of PMP and 50. mu.L of 0.3mol/L of NaOH solution were added to the standard monosaccharide and the acid-hydrolyzed PAT-W solution, and the mixture was reacted in a water bath at 70 ℃ for 30min to perform pre-column derivatization of PMP, and then neutralized to neutrality with 50. mu.L of 0.3mol/L of HCl. The obtained product is detected by high performance liquid chromatography, and a DAD detector is selected. The HPLC column temperature was 30 ℃ and the chromatography column was a Zorbox Eclipse XDB-C18 column (4.6 mm. times.250 mm, 5 μm) with a wavelength of 245 nm. Detecting that the mobile phase A is acetonitrile and the mobile phase B is 0.05mol/L phosphate buffer solution. Time gradient elution for 0-60min, initial set to mobile phase a: mobile phase B ═ 17%: 83%, finally eluted to the ratio of mobile phase a: mobile phase B is 20%: 80% and the sample amount is 10 μ L.
Step 2: and eluting with deionized water, and detecting the molecular weight of PAT-W by Agilent high performance liquid chromatography-evaporative light scattering detector (HPLC-ELSD). Preparing 1mL of 2mg/mL PAT-W and dextran standard (T5, T12, T41, T100 and T200) solution, and performing TSK Gel G6000 PWXL chromatography with N as carrier gas 2 The gas flow rate was 2.5L/min, and the sample volume was 10. mu.L. The molecular weight was measured as 2.98X 10 using standard curves of logarithm of relative molecular mass (LgMw) and retention time (Rt) of standards 4 Da。
Example 3: therapeutic effect of Armillaria mellea mycelium polysaccharide PAT-W on oral ulcer
The prepared Armillariella tabescens mycelium polysaccharide PAT-W is used as a raw material, and the effect of the Armillariella tabescens mycelium polysaccharide on treating the oral ulcer is evaluated by an experiment by utilizing an oral ulcer rat model.
1. Preparation of rat model for treating oral ulcer
Selecting 48 SPF SD female rats (SCXK (Anhui) 2017-001) with weight of 250 +/-10 g from the experimental animal center of Anhui medical university, and randomly dividing the rats into a normal group, an ulcer model group and 400mg/kg vitamin B 2 Positive drug group, 100mg/kg PAT-W low dose group, 200mg/kg medium dose group, 400mg/kg high dose group, 8 per group. Except for the normal group, the oral ulcer model was established for each group of rats.
The method comprises the following steps: a medical sterilized cotton swab is dipped in 0.6mg/mL phenol solution and burned on the mucous membrane at the left side of the oral cavity for 30 s. After 2 hours, 0.05mL of 2X 10 is injected under the burning mucous membrane tissue 3 CFU/mL of Staphylococcus aureus was used to simulate oral bacterial infection after trauma.
The rats in the blank group were treated with physiological saline. Rats were observed after 24h for oral ulcer formation. Except for the normal group, the rats of the model group, the positive medicine group and the PAT-W treatment group with low, medium and high doses successfully establish the oral ulcer model, the buccal mucosa of the rat presents an elliptic or circular ulcer surface, the surface is provided with a gray false membrane, and the diameter is 4.0mm-5.0 mm. The administration is carried out 1d after the model is made, and the administration method of the positive medicine group is that 0.3mL of 400mg/kg vitamin B is dipped in a medical sterilized cotton swab 2 (Vitamin B 2 ) The solution is applied on the ulcer surfaceFor 60s, the remaining solution was administered by gavage. The PAT-W administration mode of the low, medium and high dose groups is the same as that of the positive drug group. The normal control group and the model control group were given an equal amount of physiological saline, and each group was given 1 time per day for 7 days continuously, and changes in body weight and ulcer surface were recorded per day. After 7d of anaesthesia, the rats were sacrificed and their ulcer tissues were taken and their contents of inflammatory factors, epidermal growth factor, H, were determined&E, analyzing pathological changes by staining; oral mucus is taken and analyzed for relative abundance of oral flora. Experimental data differential significance analysis was performed using GraphPad Prism 8.3 software, oral flora abundance was based on high throughput sequencing analysis of 16 srna.
2. Results of the experiment
(1) As can be seen from Table 1, the weight of the ulcer rats in 7d was significantly reduced in the model group due to oral erosion, compared to the normal group. The physiological saline and VitaminB were administered from day 1 2 And performing intragastric administration treatment on the armillaria mycelium polysaccharide dressing. The results showed that the body weight of the model group was still continuously decreasing; and Vitamin B 2 Although the weight of the rats in the group is reduced to relieve, the weight of the rats is recovered from the fifth day; the weight of the high-dose armillariella polysaccharide group rises from 3 days, which shows that the armillariella mycelium polysaccharide can obviously improve the emaciation symptom of the ulcer rats.
Table 1 change in body weight of rats (g) (n-8,
)
| group of | |
Day 1 | Day 3 | |
Day 7 |
| Blank group | 251.16±0.99 | 251.92±1.32 | 253.17±1.30 | 253.83±1.33 | 254.50±1.39 |
| Model set | 251.08±3.67 | 248.92±4.17 | 245.92±3.53 | 244.67±2.53 | 246.00±2.82 |
| Positive drug group | 253.33±2.52 | 252.42±2.29 | 249.75±2.13 | 248.25±4.65 | 250.17±4.26 |
| Low dose group | 247.00±5.08 | 244.92±4.62 | 242.33±4.30 | 242.33±4.90 | 244.25±4.60 |
| Middle dose group | 250.50±2.45 | 248.08±2.97 | 245.83±1.80 | 247.75±1.73 | 249.08±1.90 |
| High dose group | 252.00±2.51 | 250.42±2.01 | 248.25±3.09 | 250.67±2.43 | 251.42±2.54 |
(2) As can be seen from Table 2, except for the normal group, after the model 1d, the rats of the model group, the positive drug group and the low, medium and high doses of armillaria polysaccharide all showed oral ulcer surfaces with substantially the same size. Respectively administering physiological saline and Vitamin B from 1d 2 And the armillaria tabescens mycelium polysaccharide is applied and then is subjected to intragastric administration, and the result shows that although the ulcer surface of the model group has certain self-healing property, the healing degree is slow; compared with the model group, the positive medicine group and the low-medium high-dose group of the armillaria polysaccharide obviously promote the healing of the ulcer surface (P)<0.05 or P<0.01); with same concentration of Vitamin B 2 Compared with the Vitamiban B, the healing degree of the ulcer rats treated by the high-dose Armillariella tabescens polysaccharide is better than that of the Vitamin B 2 。
TABLE 2 variation of ulcer wound area (mm) in rats 2 )(n＝8，
)
| Group of | Day 1 | Day 3 | |
Day 7 |
| Blank group | - | - | - | - |
| Model set | 4.65±0.53 | 4.09±0.12 | 3.49±0.48 | 2.85±0.65 |
| Positive drug group | 4.68±0.13 | 3.52±0.36 | 2.07±0.16** | 0.91±0.36** |
| Low dose group | 4.63±0.81 | 3.99±0.87 | 3.62±0.41 | 2.14±0.14 |
| Middle dose group | 4.67±0.12 | 3.63±0.29* | 2.52±0.15* | 1.28±0.31* |
| High dose group | 4.60±0.23 | 3.15±0.14* | 1.94±0.51** | 0.87±0.25** |
Note: -no emergence of ulcer surface; p <0.05, significant, P <0.01, very significant compared to model group.
(3) The contents of tumor necrosis factor alpha (TNF-alpha), interleukin 6(IL-6) and interleukin 1 beta (IL-1 beta) are important detection indexes of ulcer tissue inflammation, and when the content of inflammatory factors is in a stable content, ulcer mucosa tissue can be promoted to heal without being damaged by inflammation. The results are shown in Table 3: compared with the blank group, the indexes of TNF-alpha, IL-6, IL-1 beta and the like in the ulcer tissues of the rats in the model group are obviously increased (P)<0.01); comparison with the model group, Vitamin B 2 And the low, medium and high dose of the Leuconostoc polysaccharide, the IL-6 and the IL-1 beta are obviously reduced (P)<0.05、P<0.01 or P<0.001); and the same concentration of Vitamin B 2 In contrast, the decrease of inflammatory factors after the treatment of the high-dose armillaria polysaccharide is not obvious, but the value is lower than that of Vitamin B 2 。
Epidermal Growth Factor (EGF) can promote cell proliferation and is an important index for detecting epithelial cell regeneration. The results are shown in Table 3: EGF was significantly reduced in the ulcerated mucosal tissues of the model group compared to the blank group (P)<0.01); compared with the model group, EGF in the positive medicine group and the low-medium high-dose group of the armillaria polysaccharide is obviously increased (P)<0.05); with the same concentration of Vitamin B 2 Compared with the prior art, after the high-dose armillaria polysaccharide is used for treating the ulcer rats, the reduction degree is not statistically different, but is numerically superior to Vitamin B 2 。
The results show that: the content of inflammatory factors of the rat oral ulcer caused by mechanical wound combined with bacterial infection is obviously abnormal, and the application of the armillariella mycelium polysaccharide has obvious improvement effect on the level of the inflammatory factors of the oral ulcer. The Armillariella tabescens mycelium polysaccharide can promote epidermal growth factor secretion and cell proliferation to promote the healing of ulcer surface. More importantly, the index detection result shows that the polysaccharide of the armillaria tabescens mycelium is superior to the positive control medicament with the same concentration.
Table 3 contents (pg/mg) of inflammatory factors and epidermal growth factors of ulcer tissues of rats (n-8,
)
note: compared with the blank group, # # P <0.01, very significant; # P <0.001, very significant. P <0.05, significant compared to model group; p <0.01, very significant; p <0.001, extremely significant.
As shown in figure 4, the normal group of rats has complete oral mucosa tissues, clear epithelial cell structure, ordered arrangement and no inflammatory cell infiltration; compared with the normal group, the mucosa tissue of the model group has obvious inflammatory cell infiltration, and the whole epidermis tissue is broken and is accompanied with the exosmosis of the red blood cells; compared with the model group, the rat mucous epithelium tissue is basically completely recovered and has no obvious inflammatory cell infiltration particularly in the treatment group of the high-dose leucin polysaccharide.
As shown in fig. 5 and 6, the diversity analysis of microorganisms α and β by high throughput sequencing. It can be found that the abundance of oral bacteria in the model group is very significantly reduced compared to the normal group; compared with the model group, the abundance of the floras of the positive medicine group and the low-medium dosage group of the armillaria polysaccharide is improved; the flora enrichment of the high-dose group of the armillaria tabescens polysaccharide is obviously adjusted, the abundance and the uniformity of the flora are promoted, the flora imbalance is improved, and the adjusting effect is better than that of the positive medicine group.
Claims (3)
1. A polysaccharide of mycelia of armillaria tabescens, which is characterized in that:
the monosaccharide composition and the molar ratio of the polysaccharide of the mycelia of the armillaria tabescens are that mannose, galacturonic acid, glucose and arabinose are 9.83:14.52:17.45: 8.63;
the molecular weight of the Armillariella tabescens mycelium polysaccharide is 2.95 × 10 4 Da。
2. Use of the polysaccharide of the mycelium of armillaria tabescens according to claim 1, wherein:
the Armillariella tabescens mycelium polysaccharide is used for preparing a medicinal preparation with the function of treating oral ulcer.
3. Use according to claim 2, characterized in that:
the pharmaceutical preparation can obviously reduce the level of inflammatory factors, improve the content of epidermal growth factors, reduce the infiltration of inflammatory cells and adjust the richness and uniformity of oral flora.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210649789.8A CN115010822B (en) | 2022-06-09 | 2022-06-09 | Armillarisin mycelium polysaccharide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210649789.8A CN115010822B (en) | 2022-06-09 | 2022-06-09 | Armillarisin mycelium polysaccharide and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115010822A true CN115010822A (en) | 2022-09-06 |
| CN115010822B CN115010822B (en) | 2023-06-13 |
Family
ID=83072726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210649789.8A Active CN115010822B (en) | 2022-06-09 | 2022-06-09 | Armillarisin mycelium polysaccharide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115010822B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115521385A (en) * | 2022-11-07 | 2022-12-27 | 安徽大学 | Armillaria tabescens mycelium polysaccharide, preparation method thereof and application thereof in anti-tumor |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1596585A (en) * | 2004-08-12 | 2005-03-23 | 敖宗华 | Large scale liquid deep fermentation for producing brilliant bacterial mycellium powder and its polysaccbaride technology |
| US20060013825A1 (en) * | 2004-07-16 | 2006-01-19 | Medimush Aps | Immune modulating compounds from fungi |
| KR20080079962A (en) * | 2007-02-28 | 2008-09-02 | 윤종원 | Hypoglycemic exopolysaccharides from tremella fuciformis mycellium and a preparation method thereof |
| CN111253496A (en) * | 2020-01-21 | 2020-06-09 | 安徽大学 | Armillariella tabescens mycelium polysaccharide with blood sugar reducing effect |
| CN113831419A (en) * | 2021-09-28 | 2021-12-24 | 安徽大学 | Armillariella tabescens mycelium polysaccharide and its preparation method and bacteriostatic use |
-
2022
- 2022-06-09 CN CN202210649789.8A patent/CN115010822B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060013825A1 (en) * | 2004-07-16 | 2006-01-19 | Medimush Aps | Immune modulating compounds from fungi |
| CN1596585A (en) * | 2004-08-12 | 2005-03-23 | 敖宗华 | Large scale liquid deep fermentation for producing brilliant bacterial mycellium powder and its polysaccbaride technology |
| KR20080079962A (en) * | 2007-02-28 | 2008-09-02 | 윤종원 | Hypoglycemic exopolysaccharides from tremella fuciformis mycellium and a preparation method thereof |
| CN111253496A (en) * | 2020-01-21 | 2020-06-09 | 安徽大学 | Armillariella tabescens mycelium polysaccharide with blood sugar reducing effect |
| CN113831419A (en) * | 2021-09-28 | 2021-12-24 | 安徽大学 | Armillariella tabescens mycelium polysaccharide and its preparation method and bacteriostatic use |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115521385A (en) * | 2022-11-07 | 2022-12-27 | 安徽大学 | Armillaria tabescens mycelium polysaccharide, preparation method thereof and application thereof in anti-tumor |
| CN115521385B (en) * | 2022-11-07 | 2023-11-03 | 安徽大学 | Armillarisin mycelium polysaccharide, preparation method thereof and application thereof in resisting tumors |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115010822B (en) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100858569B1 (en) | Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs | |
| JP4010768B2 (en) | A new pectic polysaccharide purified from Angelica, Gigas and Nakai, its purification method and its use as an immunostimulant | |
| CN108530551B (en) | Preparation of fritillaria polysaccharide and application of fritillaria polysaccharide in preparation of antitumor drugs | |
| CN101560267A (en) | Preparation method of polysaccharide selenite | |
| CN115010822B (en) | Armillarisin mycelium polysaccharide and application thereof | |
| CN111514160A (en) | Application of schisandra chinensis polysaccharide in preparation of medicines or health-care products for treating inflammatory bowel diseases | |
| CN107854507B (en) | Method for extracting flavonoid component from folium artemisiae argyi | |
| CN112961262A (en) | Passiflora edulis pericarp acidic polysaccharide, preparation method and application thereof | |
| WO2017177934A1 (en) | Applications of hyacinth bletilla extract or konjak extract in treatment of leukopenia | |
| CN112321737B (en) | Oyster mushroom polysaccharide selenoside-II, preparation method thereof and application thereof in preparation of medicines for specifically killing non-small lung adenocarcinoma | |
| CN112724270B (en) | Low-molecular-weight alfalfa polysaccharide, preparation method thereof and application of low-molecular-weight alfalfa polysaccharide in regulating intestinal flora | |
| CN109527583B (en) | New application of morchella sporophore polypeptide | |
| CN115010823B (en) | Plantain seed polysaccharide for regulating intestinal flora and preparation method and application thereof | |
| CN108078868B (en) | Antiallergic composition for skin care products | |
| CN110218262A (en) | Application of the low sulphated heteroglycan rich in glucuronic acid in brown alga source in preparation treatment diabetes B drug | |
| CN112237588B (en) | Application of oyster mushroom polysaccharide selenoside-III anticancer active ingredient in preparation of medicine for resisting prostate cancer | |
| CN1695686A (en) | Injection preparation of 'Zhenqi' inuse for strengthening the body resistance, and preparation method | |
| CN1288747A (en) | Composite medicine containing dihydromyricetrin | |
| CN113144167A (en) | Fermented small-molecule peptide mixed solution with uric acid reducing effect and preparation method and application thereof | |
| CN114470007A (en) | Wound external composition containing lactic acid bacteria fermentation product and use thereof | |
| JPH02134325A (en) | Remedy for aids and production thereof | |
| CN115521385B (en) | Armillarisin mycelium polysaccharide, preparation method thereof and application thereof in resisting tumors | |
| CN1284548C (en) | Preparation technology of supplementing kind capsule | |
| CN113603808B (en) | Modified algin, preparation method and application thereof in preparation of medicine for promoting gastrointestinal peristalsis | |
| CN113980152B (en) | Inonotus obliquus homogeneous polysaccharide and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |